BofA points to the Eli Lilly market that could outsize the U.S.
Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came ...
Read the full story at TST (Full) - (Official Feed) →